Cargando…

Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)

BACKGROUND: Epistaxis is the most common symptom of hereditary hemorrhagic telangiectasia (HHT), affecting more than 98% of adults with HHT, with significant impact on quality of life. Floseal® has been shown to be effective for the management of anterior epistaxis, but has yet to be thoroughly eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, John M., Wu, Vincent, Faughnan, Marie E., Lasso, Andrea, Figol, Andrea, Kilty, Shaun J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794791/ https://www.ncbi.nlm.nih.gov/pubmed/31615556 http://dx.doi.org/10.1186/s40463-019-0379-y

Ejemplares similares

Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia—Preliminary results from a randomized controlled trial
por: Wu, Vincent, et al.
Publicado: (2021)

Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
por: Kilian, Alexandra, et al.
Publicado: (2020)

Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence
por: de Gussem, Els M., et al.
Publicado: (2020)

Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial
por: Mei-Zahav, Meir, et al.
Publicado: (2020)

Socioeconomic status and anterior epistaxis in adult population
por: Masoudian, Pourya, et al.
Publicado: (2017)

TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial
por: Andorfer, Kornelia E. C., et al.
Publicado: (2022)

Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia
por: Thompson, K. P., et al.
Publicado: (2022)

Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)
por: Zarrabeitia, Roberto, et al.
Publicado: (2017)

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
por: Guilhem, Alexandre, et al.
Publicado: (2017)

Synthetic dural graft septoplasty in epistaxis from hereditary hemorrhagic telangiectasia
por: Burckhardt B, Wilfred, et al.
Publicado: (2013)

Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management
por: Chin, Christopher J., et al.
Publicado: (2016)

A case report of hepatopulmonary syndrome in hereditary hemorrhagic telangiectasia (HHT): Not all right-to-left shunting in HHT is due to pulmonary arteriovenous malformations
por: Krishnan, Sheila, et al.
Publicado: (2018)

Severity score for hereditary hemorrhagic telangiectasia
por: Latino, Giuseppe A, et al.
Publicado: (2014)

An outcomes analysis of anterior epistaxis management in the emergency department
por: Newton, E., et al.
Publicado: (2016)

Determining the hospital cost of anterior epistaxis treatment modalities at a Canadian tertiary care centre
por: Nithianandan, Harrish, et al.
Publicado: (2019)

Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry
por: Gaetani, Eleonora, et al.
Publicado: (2020)

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation
por: Joyce, Katie E., et al.
Publicado: (2022)

Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia
por: Thompson, Andrew B., et al.
Publicado: (2014)

Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?
por: Shovlin, Claire L., et al.
Publicado: (2016)

Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
por: Le, Thi Thao Truc, et al.
Publicado: (2022)

Predictors of mortality in patients with hereditary hemorrhagic telangiectasia
por: Thompson, K. P., et al.
Publicado: (2021)

Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
por: Mei-Zahav, Meir, et al.
Publicado: (2017)

Hereditary hemorrhagic telangiectasia presenting as a recurrent epistaxis in an adolescent: A case report
por: Acharya, Ratna, et al.
Publicado: (2021)

Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia
por: FIORELLA, M.L., et al.
Publicado: (2012)

Circulating Angiogenic Cell Dysfunction in Patients with Hereditary Hemorrhagic Telangiectasia
por: Zucco, Liana, et al.
Publicado: (2014)

P19 An audit to improve ENT SHO confidence in using Floseal in the management of epistaxis
por: Ringrose, T, et al.
Publicado: (2021)

Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience
por: Pagella, Fabio, et al.
Publicado: (2021)

Endoglin involvement in integrin-mediated cell adhesion as a putative pathogenic mechanism in hereditary hemorrhagic telangiectasia type 1 (HHT1)
por: Rossi, Elisa, et al.
Publicado: (2015)

Association of common candidate variants with vascular malformations and intracranial hemorrhage in hereditary hemorrhagic telangiectasia
por: Pawlikowska, Ludmila, et al.
Publicado: (2018)

Hereditary Hemorrhagic Telangiectasia
por: Kamath, Nagesh, et al.
Publicado: (2015)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

Long-term efficacy assessment of current treatment options for epistaxis in HHT
por: Dür, Cilgia, et al.
Publicado: (2021)

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
por: Faughnan, Marie E., et al.
Publicado: (2018)

Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
por: Baysal, Mehmet, et al.
Publicado: (2019)

Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding
por: Beckman, Joan D., et al.
Publicado: (2020)

Targeting under-diagnosis in hereditary hemorrhagic telangiectasia: a model approach for rare diseases?
por: Latino, Giuseppe A, et al.
Publicado: (2014)

Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia
por: Thompson, K. P., et al.
Publicado: (2021)

High-Output Heart Failure Contributing to Recurrent Epistaxis Kiesselbach Area Syndrome in a Patient With Hereditary Hemorrhagic Telangiectasia
por: Bhattad, Venugopal Brijmohan, et al.
Publicado: (2017)

Silicone septal splint for recurrent epistaxis in HHT patients: experience of a national referral centre
por: Matti, Elina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_81ns0iam72hjm7b2kfru6b3oh7